The short answer
The bleeding risk of turmeric supplements with dabigatran etexilate is not well established. A small human study was reassuring for its tested Curcuma longa preparation, while a bleeding case involving concentrated curcumin used different blood-thinning medicines. Neither establishes the outcome of this exact pair.
What this answer covers
Oral Curcuma longa (turmeric) with adult oral dabigatran etexilate capsules. Whole turmeric, concentrated curcumin and enhanced-absorption mixtures are distinct.
- Supplement or preparation
- Turmeric
- Medication ingredient
- dabigatran etexilate
What human research is available?
A randomized study enrolled 25 healthy volunteers for each herb and examined Curcuma longa alone and with aspirin in three-week phases. It found no clinically relevant overall coagulation impairment or significant bleeding. The accessed abstract does not provide enough formulation detail to apply the result to every turmeric supplement.
What about reports of serious bleeding?
A published case described a thigh hematoma after concentrated curcumin was added to apixaban plus clopidogrel. It involved several other bleeding risk factors, did not measure apixaban concentrations and did not test dabigatran. It is relevant as a cautionary signal, but it cannot establish a specific turmeric/dabigatran interaction.
Why keep the names and forms separate?
Dabigatran etexilate is the swallowed prodrug. The body converts it to dabigatran, which directly inhibits thrombin. Turmeric contains multiple constituents, while a curcumin capsule may concentrate one group of compounds or add absorption-enhancing ingredients. A positive or negative result for one preparation does not automatically describe another. Use the exact label, daily amount and full ingredient list when seeking advice.
Is there a recommended time gap?
No reliable spacing interval was established in the inspected evidence, and a universal instruction to avoid all turmeric exposures is not supported. Review optional supplements with the prescriber, especially with aspirin or a bleeding history. Keep taking the anticoagulant as directed and seek prompt care for new bleeding, with urgent assessment for severe symptoms.
Evidence and practical considerations
Side effects & toxicity
The bleeding risk of turmeric supplements with dabigatran etexilate is not well established. A small human study was reassuring for its tested Curcuma longa preparation, while a bleeding case involving concentrated curcumin used different blood-thinning medicines. Neither establishes the outcome of this exact pair.
- Exact scope
- Oral Curcuma longa (turmeric) with adult oral dabigatran etexilate capsules. Whole turmeric, concentrated curcumin and enhanced-absorption mixtures are distinct. with adult oral dabigatran etexilate mesylate capsules; active dabigatran produced after absorption
- Medication form and route
- adult oral dabigatran etexilate mesylate capsules; active dabigatran produced after absorption
- Timing or duration
- Concurrent oral use. Source-specific durations are recorded in the evidence entries; no unstudied duration threshold or separation schedule is inferred.
What remains uncertain
- Healthy volunteer/aspirin trial and curcumin/apixaban/clopidogrel case are indirect for both medication and preparation. No quantitative dabigatran interaction or validated timing rule.
Factors that may matter: Exact supplement preparation, dose and additional ingredients; Kidney function, age, bleeding history and other antiplatelet or anticoagulant medicines; Current medication formulation and recent supplement start or stop.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving oral dabigatran etexilate capsules.
P-gp induction reduces active dabigatran exposure. P-gp inhibition and impaired renal function increase exposure. Capsules must be swallowed intact. RE-LY trough concentrations were not appreciably changed by concomitant PPIs or H2 blockers.
How this applies: Establishes the exact medicine’s mechanism, baseline bleeding precautions and formulation/transport limitations; it does not establish this supplement-specific interaction. Exact scope: Oral Curcuma longa (turmeric) with adult oral dabigatran etexilate capsules. Whole turmeric, concentrated curcumin and enhanced-absorption mixtures are distinct.
Named medicine dose adjustments cannot be extrapolated to untested herbs. Label silence about a supplement does not prove compatibility. Capsule results must not be generalized to every formulation.
Source 2: original randomized human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 25 healthy volunteers enrolled for each herbal preparation; 24 Curcuma and 23 Panax participants in reported platelet results.
No clinically relevant overall coagulation impairment or significant bleeding; the herbs did not further aggravate aspirin-induced platelet inhibition.
How this applies: Provides preparation-specific human coagulation observations for Curcuma longa or its related botanical preparation with aspirin, not dabigatran etexilate. No direct medication substitution is assumed. Exact scope: Oral Curcuma longa (turmeric) with adult oral dabigatran etexilate capsules. Whole turmeric, concentrated curcumin and enhanced-absorption mixtures are distinct.
Small healthy-volunteer study; exact preparation doses unavailable in accessed abstract. Not apixaban or dabigatran, not all extracts or rare-event safety.
Source 3: original human case report
jclinmedcasereports.com · Source check Sep 10, 2026
Population: 74-year-old man with atrial fibrillation, coronary disease, renal transplant and multiple medicines.
A large thigh hematoma and anemia required transfusion. Curcumin had already stopped and apixaban was withheld during admission; the patient stabilized.
How this applies: Two bridges are required: apixaban to dabigatran etexilate, and concentrated curcumin to whole Curcuma longa. Neither bridge establishes a proven interaction. Exact scope: Oral Curcuma longa (turmeric) with adult oral dabigatran etexilate capsules. Whole turmeric, concentrated curcumin and enhanced-absorption mixtures are distinct.
Single uncontrolled polypharmacy case with clopidogrel, thrombocytopenia and renal history. No apixaban concentration measurement, rechallenge or isolated curcumin effect. It does not test culinary turmeric or every extract.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current labels and targeted original sources assessed; all current available claims adjudicated and consumer article prepared. Uncertainty and indirect evidence retained. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: 30214d8031ed50e0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.